Key result
Neonatal PDA closure is linked to a ~28% reduction in indomethacin volume of distribution.
Why the study?
Indomethacin pharmacokinetics in neonates with patent ductus arteriosus were not well characterized, including changes before and after PDA closure.
How does patent ductus arteriosus closure affect indomethacin pharmacokinetics in neonates?
Population
18 neonates with patent ductus arteriosus
Comparison
Pre-PDA closure vs post-PDA closure pharmacokinetics
Design
Observational pharmacokinetic study
Authors
Loading...
May support TDM for indomethacin dosing in neonates; leaves open effects on PDA closure and toxicity.
Observational (n=18)
How does patent ductus arteriosus closure affect indomethacin pharmacokinetics in neonates?
Absolute Event Rate: 0.26% vs 0.36%
p-value: p=<0.001
PDA closure significantly reduces the volume of distribution of indomethacin in neonates, highlighting the impact of physiological changes on pharmacokinetics.
Gál et al. (1991) conducted an observational in Patent ductus arteriosus (n=18). Indomethacin vs. Pre-PDA closure was evaluated on Indomethacin volume of distribution (p=<0.001). Indomethacin volume of distribution decreased significantly following patent ductus arteriosus closure in neonates (0.36 vs 0.26 L/kg; P<0.001).